Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853963 | 1.00 | APLNR (0.44) | APLNRPTK2BRD4L3MBTL1ADRA2A | |
| SCHEMBL2609315 | 0.82 | PTK2 (0.38) | APLNRPTK2BRD4L3MBTL1ADRA2A | |
| SCHEMBL1854293 | 0.80 | PTK2 (0.37) | APLNRPTK2BRD4L3MBTL1ADRA2A | |
| SCHEMBL4278366 | 0.80 | PTK2 (0.37) | APLNRPTK2BRD4L3MBTL1ADRA2A | |
| SCHEMBL24501187 | 0.79 | PYGL (0.46) | APLNRBRD4L3MBTL1ADRA2AADRA2B | |
| SCHEMBL29108562 | 0.79 | PYGL (0.46) | APLNRBRD4L3MBTL1ADRA2AADRA2B | |
| SCHEMBL18264342 | 0.79 | TSHR (0.40) | APLNRPTK2BRD4L3MBTL1ADRA2A | |
| SCHEMBL29108209 | 0.79 | PYGL (0.46) | APLNRBRD4L3MBTL1ADRA2AADRA2B | |
| SCHEMBL30640205 | 0.79 | PYGL (0.46) | APLNRBRD4L3MBTL1ADRA2AADRA2B | |
| SCHEMBL30640220 | 0.79 | PYGL (0.46) | APLNRBRD4L3MBTL1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4558224-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-05-28 | — | — | EP | disclosed |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| CN-119119033-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| WO-2015007682-A1 | PESTICIDE COMPOUNDS | BASF SE (DE) | 2015-01-22 | — | — | WO | disclosed |
| CN-101522693-B | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine deirvatives and their use in therapy | ASTRAZENECA AB | 2012-01-04 | — | — | CN | disclosed |
| CN-101516893-B | 5, 7-disubstituted [1,3] thiazolo [4,5-D ] pyrimidin-2 (3H) -one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2011-11-30 | — | — | CN | disclosed |
| CN-101312965-B | Morpholine type cinnamamide compound | EISAI R&D MAN CO LTD | 2011-07-20 | — | — | CN | disclosed |
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| CN-101522693-A | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine deirvatives and their use in therapy | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | CN | disclosed |
| CN-101516893-A | Novel 5, 7-disubstituted [1,3] thiazolo [4, 5-D ] pyrimidin-2 (3H) -one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2009-08-26 | — | — | CN | disclosed |
| CN-101312965-A | Morpholine type cinnamamide compound | EISAI R&D MAN CO LTD (JP) | 2008-11-26 | — | — | CN | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | APLNR 4644/4885PTK2 2594/4885BRD4 1653/4885 |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLH | APLNR 4735/4885PTK2 2083/4885BRD4 1635/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | APLNR 1439/4885PTK2 4321/4885BRD4 2042/4885 |
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | APLNR 3965/4885PTK2 2502/4885BRD4 765/4885 |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | APLNR 1778/4885PTK2 444/4885BRD4 553/4885 |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | APLNR 4654/4885PTK2 3447/4885BRD4 2/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | APLNR 4765/4885PTK2 3458/4885BRD4 3/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | APLNR 1439/4885PTK2 4321/4885BRD4 2042/4885 |
| US-12509454-B2 | Thiadiazolyl derivatives | POLD1, POLQ, DNA2 | APLNR 4866/4885PTK2 2696/4885BRD4 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.